Pharmacokinetic profiles of glycyrrhizin in patients with chronic hepatitis

Biopharm Drug Dispos. 1993 Oct;14(7):609-14. doi: 10.1002/bdd.2510140707.

Abstract

The pharmacokinetics of glycyrrhizin (G) in eight patients with chronic hepatitis receiving chronically i.v. administration of 120 mg dose of G was investigated. The plasma concentration of G in the patients after dosing declined in a monophasic manner. However, the pharmacokinetic profiles varied among patients. The mean elimination half-life (t1/2) and the total body clearance (CLtot) were 6.0 h (range 4.3-10.7 h) and 7.9 ml h-1 kg-1 (4.5-12.7 ml h-1 kg-1), respectively. The variation of the CLtot for G was closely related to that of aspartate aminotransferase (r = -0.739, p < 0.05) and alanine aminotransferase (r = -0.783, p < 0.05) activities in the plasma.

MeSH terms

  • Adult
  • Aged
  • Alanine Transaminase / blood
  • Antiviral Agents / pharmacokinetics*
  • Aspartate Aminotransferases / blood
  • Chronic Disease
  • Female
  • Glycyrrhetinic Acid / analogs & derivatives*
  • Glycyrrhetinic Acid / blood
  • Glycyrrhetinic Acid / pharmacokinetics
  • Glycyrrhetinic Acid / therapeutic use
  • Glycyrrhizic Acid
  • Hepatitis / blood
  • Hepatitis / drug therapy*
  • Humans
  • Injections, Intravenous
  • Liver Function Tests
  • Male
  • Metabolic Clearance Rate
  • Middle Aged

Substances

  • Antiviral Agents
  • Glycyrrhizic Acid
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Glycyrrhetinic Acid